Suggested remit: To appraise the clinical and cost effectiveness of elranatamab within its marketing authorisation for treating relapsed or refractory multiple myeloma after 3 therapies.
 
Status In progress
Technology type Medicine
Decision Selected
Process STA Standard
ID number 4026

Provisional Schedule

Committee meeting: 2 15 May 2024
Expected publication 05 June 2024

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
14 March 2024 Committee meeting: 1
14 August 2023 Invitation to participate
16 May 2023 Following the changes to remove technical engagement as standard from appraisal timelines, the timelines for the appraisal of Elranatamab for treating refractory multiple myeloma after 3 standard therapies have been revised. It is anticipated that the appraisal will begin in early-August 2023 when we will write to you about how you can get involved.
16 November 2022 - 14 December 2022 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
02 December 2022 As you will be aware, the Department for Health & Social Care has asked NICE to conduct an appraisal of Elranatamab for treating refractory multiple myeloma after 3 standard therapies. Please note that following on from advice received from the company this appraisal has been rescheduled to align with latest regulatory expectations. Therefore, we now anticipate that the appraisal will begin in mid-April 2023 when we will write to you about how you can get involved.
28 January 2022 In progress. DHSC referral received

For further information on our processes and methods, please see our CHTE processes and methods manual